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ABSTRACT
Background:Mesenteric ischemia and reperfusion (I/R) syndrome (MIRS) has
been considered a clinicopathologic entity associated with a variety of clinically severe
conditions with decreased intestinal blood flow and has been known to induce I/R
damage in various organs. Sirolimus (SRL), a macrolide antibiotic isolated from a
strain of Streptomyces hygroscopicus, is a potent and nonnephrotoxic immunosuppressant.
Objective: This study was designed to investigate the potential impact of
sirolimus on MIRS-induced I/R damage in renal, intestinal, pulmonary, and hepatic
tissues in an experimental rat model.
Methods: Twenty-four male Sprague-Dawley rats, aged 6 to 8 weeks and
weighing 280 (20 g), were studied. Using computer-generated random numbers,
ats were assigned to 1 of the following 3 groups: group 1 (I/R group, n  8), group
(I/R  sirolimus group, n  8), and group 3 (control group, n  8). Sirolimus, in
1 mg/mL (60 mL) solution, was administered intraperitoneally in a dose of 1.5
g/kg/d to the rats assigned to group 2 starting from 3 days before the surgical
rocedure. In surgery, a laparotomy was performed to clamp the superior mesenteric
rtery and, thus, induce bowel ischemia in groups 1 and 2. After 60 minutes of
schemia, the microvascular clamp on the superior mesenteric artery was removed for
hours of reperfusion. Soon after experimental induction of MIRS, bowel, lung,
idney, and liver specimens from each animal were harvested for both biochemical
nd histopathologic analysis.
Results: There were statistically significant differences between groups 1 and
3 with regard to degrees of intestinal (P  0.001), hepatic (P  0.001), renal (P 
0.001), and pulmonary (P  0.01) I/R damage. The lung specimens from group 2
had less inflammation and perivascular edema formation compared with specimens
from group 1, but no statistical significance was observed between the groups
(P  0.33). There were statistically significant differences between groups 1 and
2 with regard to degrees of intestinal, hepatic, and renal I/R damage (P  0.001
for all).
Accepted for publication March 21, 2011. doi:10.1016/j.curtheres.2011.03.004
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Current Therapeutic ResearchConclusion: The findings of the present study demonstrate the attenuating
ffects of sirolimus on I/R damage in the intestine and remote organs, including the
iver and kidney in the setting of MIRS in an experimental rat model. As a
herapeutic implication, the utility of sirolimus may be of clinical value in procedures
ssociated with a high likelihood of I/R damage, including major abdominal opera-
ions and renal transplantation. However, whether these results apply to humans is
nclear. Additional experimental and clinical studies are warranted to confirm the
linical utility of sirolimus in conditions potentially associated with I/R damage.
Curr Ther Res Clin Exp. 2011;72:79-93) © 2011 Elsevier HS Journals, Inc. All rights
eserved.
Key words: experimental model, ischemia reperfusion damage, sirolimus,
arget organs.
INTRODUCTION
Mesenteric ischemia and reperfusion (I/R) syndrome (MIRS) is a clinicopathologic
entity closely associated with a variety of clinically severe conditions, including major
surgery with decreased intestinal blood flow, acute blood loss, ileus, severe burns,
sepsis, intussusception, transplantation, mesenteric arterial occlusion, hemodynamic
shock, and multiple trauma.1–3 Therefore, it may be attributable to potential com-
lications during various medical and surgical procedures. MIRS is also associated
ith I/R damage in various organ systems, to some extent. In the setting of MIRS,
he triggers of I/R damage in bowel and in various remote organs–lung, liver, and
idney–have not yet been established; however, humoral mediators are generally
hought to play the central role in the reperfusion phase of this entity.3–6
I/R damage has two components: the ischemic phase and the reperfusion phase.
During the ischemic phase an inadequate oxygen supply is the primary determinant
of I/R damage; however, the majority of injury and apoptosis occurs during the reper-
fusion phase in which reactive oxygen species, inflammatory leukocytes, mitochondrial
dysfunction, and cytochrome C released from mitochondria into the cytosol play the most
important role. This cascade consequently leads to increased bowel permeability, gut
barrier dysfunction, and transmigration of bacteria and bacterial products into the sys-
temic pool, whereupon a systemic life-threatening condition with high rates of morbidity
and mortality occurs.3 Loss of fluid and protein from the vascular bed due to increased
ascular permeability may also result in multiple organ failure.1,2,7,8
The I/R damage in the respiratory system may be characterized by the accumu-
lation of inflammatory infiltrates, increased microvascular permeability, alveolar
capillary endothelial cell injury, and pulmonary edema. Renal I/R damage also has been
considered a common consequence of MIRS. Tissue hypoxia and subsequent pathophys-
iologic processes, including polymorphonuclear leukocytic infiltration of the renal paren-
chyma along with the activation of proinflammatory cytokines, reactive nitrogen and
oxygen species, and enhanced coagulation, may result in renal tissue damage. I/R damage
in the small intestine may be characterized by loss of a few villi with massive epithelial
lifting, mucosal necrosis, submucosal edema, hemorrhage, and ulceration.1,2,4,5,7–9
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of local and systemic I/R damage, related experimental and clinical trials have
conferred limited therapeutic implications.10–18 Sirolimus (SRL), a macrolide anti-
biotic isolated from a strain of Streptomyces hygroscopicus, is a potent and nonnephrotoxic
mmunosuppressant. Sirolimus binds the small, ubiquitous protein FKBP12, forming
complex of SRL-FKBP12 that inhibits signaling by a serine and threonine protein
inase, the mammalian target of rapamycin (mTOR). The consequent inhibition of
TOR leads to cell-cycle arrest during the G1 phase in a variety of cells including
ymphocytes, smooth muscle cells, hepatocytes, fibroblasts, and renal tubular cells.19
Sirolimus has been demonstrated to harbor attenuating effects on I/R damage in
experimental animal models.9,19–23 The present study was designed to investigate the
potential impact of sirolimus on MIRS-induced I/R damage in renal, intestinal,
pulmonary, and hepatic tissues in an experimental rat model.
MATERIALS AND METHODS
Study Design
The study was conducted at the Laboratory Animals Care Unit in accordance with
guidelines for the care and use of laboratory animals established by the Animal Ethics
Committee. The Committee approved the study design. Twenty-four male Sprague-
Dawley rats, aged 6 to 8 weeks and weighing 280 (20) g, were studied. Using
computer-generated random numbers, rats were assigned to 1 of the following 3
groups: group 1 (I/R, n 8), group 2 (I/R sirolimus, n 8), and group 3 (control,
n  8). Rats were maintained at a temperature of 22°C (2°C) and a relative
umidity of 55% (15%), with a 12-hour light:dark cycle. Tap water and chow was
vailable ad libitum throughout the acclimatization and study periods.
Chemicals and Reagents
A 1 mg/mL (60 mL) solution of sirolimus* was purchased commercially. An
intraperitoneal dose of 1.5 mg/kg/d rapamycin was administered to the rats as
described previously by Thomson,24 Walpoth,25 and Whiting.26 The dose of siroli-
us, based on the literature in which sirolimus was used as an immunosuppressant
n rats, was initiated in group 2 starting from 3 days before the surgical procedure.
he same amount of normal saline was administered intraperitoneally in groups 1 and 3.
Surgical Procedure
After an overnight fasting period, anesthesia was applied to the animals in the
groups using 5 mg/kg of xylazine† and 30 mg/kg of ketamine hydrochloride‡
administered intramuscularly before the experiment. The abdomen of each animal
was shaved and cleaned with povidone iodine solution.§ Using sterile technique, all
*Trademark: Rapamune® (Wyeth I˙laçları AS¸, Istanbul, Turkey).
†Trademark: Rompun® (Bayer Ilac Sanayi, Sisli, Istanbul, Turkey).
‡Trademark: Ketalar® (Eczacibasi Ilac San, Istanbul, Turkey).
§Trademark: IsoSol® (Merkez Laboratory, Ilac San, Istanbul, Turkey).
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Current Therapeutic Researchanimals underwent a laparotomy via a midline incision of approximately 3 cm. The
aorta and visceral arteries were exposed in the abdominal cavity, and the Treitz
ligament was also incised to better expose the superior mesenteric artery. Group 3
(control group) underwent superior mesenteric artery mobilization solely without
clamping. In groups 1 and 2, an atraumatic microvascular bulldog clamp was placed
with care across the superior mesenteric artery just at its origin from the aorta to avoid
occlusion of the superior mesenteric vein. Mesenteric ischemia was confirmed by the
loss of mesenteric pulsations and intestinal paleness. The bowel was then returned to
the abdominal cavity, and the area of incision was closed with interrupted atraumatic
4.0 silk sutures. After 60 minutes of ischemia, laparotomy was performed again to
remove the microvascular clamp on the superior mesenteric artery for 3 hours of
reperfusion. Mesenteric reperfusion was confirmed with the restoration of pulsation
and color. The bowel was then returned to the abdominal cavity, and the area of
incision was closed with 4.0 silk sutures. The bowel was left in the abdomen during
reperfusion. At the end of 3 hours, tissue samples were obtained from an area of small
intestine that was 5 cm proximal to the ileocecal region. Lung, kidney, and liver
specimens from each animal were harvested for both biochemical and histopathologic
analysis. The lung parenchyma was flushed with 10 mL of ice-cold physiologic saline
via a right ventricular puncture thorough the heart to remove blood and to interrupt
the metabolism. The other tissues were rinsed with cold saline solution, and all tissue
specimens were fixed in a 10% buffered formalin solution for histopathologic analysis.
The remaining specimens were stored at –70°C for biochemical examination.27
Histopathologic Examination
Tissue specimens were fixed in 10% formalin solution for 24 hours, then embed-
ded in paraffin and sliced into 5-m sections. Slides were stained with hematoxylin
nd eosin and examined under a light microscope. Each slide was evaluated by 2
nvestigators blinded to the experiment and data. Intestinal injury was classified into
5-tiered scale defined by Chiu et al28 as follows: grade 0, no diagnostic change;
rade 1, subepithelial layer lifting from the lamina propria, usually at the apex of the
illus; grade 2, moderate epithelial cell layer lifting from the lamina propria; grade
, loss of a few villi with massive epithelial lifting from the lamina propria with a few
enuded villi; and grade 4, disintegration of the lamina propria with ulceration and
emorrhage.
Pulmonary injury was classified into 1 of 4 grades as follows: grade 0, no diagnostic
hange; grade 1, mild neutrophil leukocyte infiltration and mild-to-moderate inter-
titial congestion; grade 2, moderate neutrophil leukocyte infiltration, perivascular
dema formation, and partial destruction of pulmonary architecture; and grade 3,
ense neutrophil leukocyte infiltration and complete destruction of pulmonary struc-
ure.29
Hepatic injury was evaluated by a point-counting method for severity of hepatic
injury using an ordinal scale as follows: grade 0, no evidence of injury; grade 1, mild
injury consisting of cytoplasmic vacuolation and focal nuclear pyknosis; grade 2,
moderate-to-severe injury with extensive nuclear pyknosis, cytoplasmic hypereosino-
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tion of hepatic cords, hemorrhage, and neutrophil infiltration.18
Renal injury was classified into 1 of 4 grades as follows: grade 0, no diagnostic
change; grade 1, tubular cell swelling, brush border loss, and nuclear condensation
with up to one third of tubular profile showing nuclear loss; grade 2, same as grade
1, but more than one third and less than two thirds of tubular profile showing nuclear
loss; and grade 3, more than two thirds of tubular profile showing nuclear loss.30
Statistical Analysis
The groups were compared using the Kruskal-Wallis test with regard to the
histopathologic findings. Groups were compared as pairs using the Mann-Whitney U
test. Bonferroni correction was performed because 3 groups were compared as pairs,
and P  0.017 was regarded as statistically significant.
RESULTS
Groups were found to be statistically different from one another with regard to the
injury grade of the tissue specimens. Statistical data for the specimens of the groups
are shown in Figure 1.
Lungs
Lung specimens from the control group (group 3) had normal histology. Mild-to-
moderate infiltration of neutrophil leukocytes, mild-to-moderate interstitial conges-
tion, perivascular edema formation, and partial destruction of the pulmonary archi-
tecture were observed in specimens from group 1. There was a statistically significant
difference between group 1 and group 3 (P  0.01). The specimens from group 2
anifested a lesser degree of inflammation and perivascular edema formation com-
ared with those from group 1, but no statistical significance was observed among the
roups (P  0.33) (Figure 2).
Liver
Liver specimens from group 3 manifested almost normal histology except 1
specimen that had mild injury consisting of cytoplasmic vacuolation and focal nuclear
pyknosis. However, there was moderate-to-severe injury with extensive nuclear py-
knosis, cytoplasmic hypereosinophilia, loss of intercellular borders, severe necrosis
with disintegration of hepatic cords, hemorrhage, and neutrophil infiltration in the
specimens from group 1 (Figure 3). In the specimens from group 2, mild injury
consisting of cytoplasmic vacuolation and focal nuclear pyknosis was observed. There
were statistically significant differences between groups 1 and 3, and between groups
2 and 3 (P  0.001 for both) (Figure 3).
Kidneys
Kidney specimens from group 3 manifested almost normal histology except in 1
specimen that had tubular cell swelling, brush border loss, and nuclear condensation
with up to one third of tubular profile showing nuclear loss. Tubular cell swelling,
brush border loss, nuclear condensation with more than one third and less than two
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from group 1. In the specimens from group 2, minimal I/R injury with no changes
to tubular cell swelling and brush border loss were observed. There were statistically
significant differences between groups 1 and 3, and between groups 1 and 2 (P 
.001 for both) (Figure 4).
Intestine
Small bowel specimens from group 3 manifested normal histology. Disintegration
Figure 1. The statistical data for specimens in the groups. Groups were compared as pairs
using Mann-Whitney U test. Bonferroni correction was performed because 3
groups were compared as pairs and P < 0.017 was regarded as statistically
significant. I/R  ischemia and reperfusion; SRL  sirolimus.of the lamina propria with ulceration and hemorrhage and loss of a few villi with
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T. Sagiroglu et al.Figure 2. Histopathology sections of lungs. (A) Group 1 (ischemia/reperfusion group):
massive neutrophil leukocyte infiltration; (B) group 3 (control group): normal
architecture; and (C) group 2: mild inflammatory infiltrate composed of neutro-
phils (hematoxylin and eosin, original magnification 50).
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Current Therapeutic ResearchFigure 3. Histopathology sections of liver. (A) Group 1: necrosis and vacuolar degenera-
tion of hepatocytes; (B) group 3: normal architecture; (C) group 2: vacuolar
degeneration less than ischemic group (hematoxylin and eosin, original magni-
fication 100).
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T. Sagiroglu et al.Figure 4. Histopathology sections of kidney. (A) Group 1: widespread necrosis of renal
tubules; (B) group 3: normal architecture; (C) group 2: nearly normal renal
tubules (hematoxylin and eosin, original magnification 50).
87
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findings observed in all specimens from group 1. The histopathologic alterations
consisting of subepithelial layer lifting from the lamina propria, usually at the apex
of the villus, were observed in the specimens from group 2. There were statistically
significant differences between groups 1 and 3, and between groups 1 and 2 (P 
.001 for both) (Figure 5).
DISCUSSION
This study demonstrates that reperfusion after a period of ischemia in a local site
(MIRS) may lead to systemic I/R damage in various organs in an experimental rat
model. More important, it also demonstrates the effects of sirolimus on MIRS-
induced I/R damage, which may be suggested to confer important therapeutic
implications. Of note, sirolimus may be considered to have systemic protective effects
because it lessens the degree of I/R damage, to some degree, in remote organs as well.
As a therapeutic implication, renal protection by the initiation of sirolimus is of
particular clinical importance; renal transplantation has been suggested as the best
treatment modality in patients with end-stage renal disease with an increase use of
donor cadaveric kidneys in the recent years. During renal transplantation, I/R damage
may be regarded as one of the risk factors for delayed graft function, acute rejection
episodes, and impaired long-term allograft survival. Ischemia is the sum of a possibly
transient warm interval before or during organ removal from the donor and a cold
interval during organ preservation and storage. Reperfusion of the kidney after
transplantation may have the potential to trigger reperfusion injury in the renal tissue
and thus may contribute to the ischemic damage. Many studies have investigated the
potential determinants and protective strategies for I/R damage after renal transplan-
tation in experimental models.19,22,23,31–36 Sirolimus, an antiproliferative immuno-
suppressant, has recently been used in human transplantation. Inman et al37 inves-
tigated the effects of cyclosporine and rapamycin on renal function after induction of
I/R damage. Sirolimus (0.17 mg/kg/d gavage) and cyclosporine A (30 mg/kg/d
intraperitoneally) were administered to rats after performing renal I/R model. The
experimental study found that the mean arterial pressure was significantly low (P 
0.01), and the glomerular filtration rate was significantly high (P  0.01) in the
sirolimus group compared with results in the cyclosporine A group. The investigators
suggested that sirolimus might be a better alternative than cyclosporine A for the
protection of renal functions after I/R damage. Although no comparison with any
other agent was made, this study also found the effects of sirolimus on I/R damage
in the renal tissue.
In MIRS, several proinflammatory mediators and endotoxins are released into the
portal system in substantial amounts, leading to hepatic injury.38 Therefore, hepatic
dysfunction may be regarded as one of the initial findings of MIRS (due to the portal
system), which may alert the clinician in the relatively early stages. Biecker et al21
conducted an experimental study on rats, investigating the effects of sirolimus on
liver fibrosis in bile duct–ligated rats. These were treated with sirolimus for 28 days.
After 28 days, liver mRNA levels of transforming growth factor 1, connective tissue
88
T. Sagiroglu et al.Figure 5. Histopathology sections of ileum. (A) Group 1: disintegration of lamina propria
with ulceration and loss of villi; (B) group 3: normal architecture; (C) group 2:
the early stages of ischemic injury reveal mild surface epithelial degeneration
(hematoxylin and eosin, original magnification 50).
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Current Therapeutic Researchgrowth factor, platelet-derived growth factor, cyclin-dependent kinase inhibitor
p27kip, and cyclin-dependent kinase inhibitor p21WAF1/CIP1 were quantified. This
xperimental study demonstrated that portal vein pressure, volume fractions of
onnective tissue, bile duct epithelium, and desmin- and actin-positive cells were all
ower in the sirolimus group compared with the control group. The investigators
oncluded that sirolimus potently inhibited the bile duct ligation-induced liver
brosis in rats and thereby might improve the hyperdynamic circulation syndrome.
he current study, notwithstanding its different design, also found the beneficial
ffects of SRL on I/R damage in the liver tissue. Puglisi et al39 hypothesized that
sirolimus might protect the small bowel against I/R damage. The authors induced
gut ischemia via occlusion of the superior mesenteric artery in this study. The results
indicate that sirolimus plays a significant role in attenuating I/R injury in the gut.
The current study revealed that there was a statistically significant difference in the
intestinal pathologies between group 1 and group 2 (P 0.001), confirming previous
literature.
However, data about the effect of sirolimus on I/R damage of the lung are still
insufficient and do not allow conclusive statements. Unlike in other specimens, the
effects of sirolimus on I/R damage in lung specimens were insignificant in the current
study. This might be attributable to the limited number of mice models or to the
presence of an alternate pathway of I/R damage in the lung that could render
sirolimus relatively ineffective. To clarify another aspect of sirolimus therapy, Yo-
shizaki et al40 investigated the effect of sirolimus on fibrosis in the tight-skin and
bleomycin-induced mouse model of systemic sclerosis. The study found sirolimus-
induced reductions in fibroblast count; levels of interleukin-4, interleukin-6, inter-
leukin-17, and transforming growth factor beta-1; and production of anti-topoi-
somerase I antibody and collagen. The authors reported that sirolimus had a
significant inhibitory effect on fibrosis in both the tight-skin and the bleomycin-
induced systemic sclerosis mice models, indicating the potent antifibrotic, antipro-
liferative, and antiinflammatory effects of sirolimus.
CONCLUSION
To our knowledge, this is the first experimental study investigating the systemic
effects of sirolimus on MIRS-induced I/R damage in target organs including lung,
intestine, kidney, and liver. The findings of this study reveal the effects of SRL on I/R
damage in the intestine and remote organs, including liver and kidney in the setting
of MIRS. As a therapeutic implication, the utility of sirolimus may be of clinical value
in procedures with a high risk of I/R damage, including major abdominal operations
and renal transplantation. Additional experimental and clinical studies are warranted
to confirm the clinical utility of sirolimus in conditions potentially associated with
I/R damage. The primary limitation of this study is the number of rats included; a
larger experimental series may confirm statistical significance in all target organs.
Comparison with another agent was not made in this study, indicating the need for
future comparative studies that may test the real efficacy of sirolimus. Finally, how
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T. Sagiroglu et al.trial results apply to humans is unclear; large-scale clinical studies are needed to
confirm the role of sirolimus in the clinical setting.
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